Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal

Synapse

Volumn 62, Issue 9, 2008, Pages 689-699

  Kitanaka, Nobue ^a   Kitanaka, Junichi ^a   Hall, F Scott ^b   Tatsuta, Tomohiro ^a   Morita, Yoshio ^a   Takemura, Motohiko ^a   Wang, Xiao Bing ^b   Uhl, George R ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Amphetamine; Cocaine; Gene and protein expression; Intracellular effector; Morphine; Transcription factor

Indexed keywords

ALCOHOL; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BUTORPHANOL; COCAINE; DIAMORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; OPIATE DERIVATIVE; PENTOBARBITAL; PROTEIN SUBUNIT; PSYCHOSTIMULANT AGENT;

ALCOHOLISM; BEHAVIOR; BRAIN REGION; DRUG ABUSE; DRUG DEPENDENCE; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; HEROIN DEPENDENCE; HUMAN; LONG TERM EXPOSURE; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANIMALS; BARBITURATES; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG TOLERANCE; ETHANOL; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 47749129211     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20543     Document Type: Review

References (88)

1. Acquas E, Carboni E, Di Chiara G. 1991. Profound depression of mesolimbic DA release after morphine withdrawal in dependent rats. Eur J Pharmacol 193:133-134.
2. Barr AM, Markou A. 2005. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 29:675-706.
3. B receptors. Pharmacol Ther 110:533-543.
4. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. 2003. Insights into G protein structure,function, and regulation. Endocr Rev 24:765-781.
5. Carlezon WA Jr, Duman RS, Nestler EJ. 2005. The many faces of CREB. Trends Neurosci 28:436-445.
6. 11 proteins in brains of rats during cocaine withdrawal. J Pharmacol Exp Ther 307:1012-1019.
7. 11 proteins in rats undergoing withdrawal. J Pharmacol Exp Ther 311:349-355.
8. Casey PJ, Gilman AG. 1988. G protein involvement in receptor-effector coupling. J Biol Chem 263:2577-2580.
9. 9-tetrahydrocannabinol produces naloxone blockable enhancement of presynaptic DA efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102:156-162.
10. Cole RL, Konradi C, Douglass J, Hyman SE. 1995. Neuronal adaptation to amphetamine and DA: molecular mechanisms of prodynorphine gene regulation in rat striatum. Neuron 14:813-823.
11. Commiskey S, Fan L-W, Ho IK, Rockhold RW. 2005. Butorphanol: effects of a prototypical agonist-antagonist analgesic on κ-opioid receptors. J Pharmacol Sci 98:109-116.
12. Contarino A, Picetti R, Matthes HW, Koob GF, Kieffer BL, Gold LH. 2002. Lack of reward and locomotor stimulation induced by heroin in μ-opioid receptor-deficient mice. Eur J Pharmacol 446:103-109.
13. Crain SM, Shen K-F. 1995. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 92:10540-10544.
14. Crawford CA, Choi FY, Kohutek JL, Yoshida ST, McDougall SA. 2004. Changes in PKA activity and Gsα and Golfα levels after amphetamine- and cocaine-induced behavioral sensitization. Synapse 51:241-248.
15. Deng HB, Yu Y, Wang H, Guang W, Wang JB. 2001. Agonist-induced μ opioid receptor phosphorylation and functional desensitization in rat thalamus. Brain Res 898:204-214.
16. Devoto P, Flore G, Pira L, Diana M, Gessa GL. 2002. Co-release of noradrenaline and DA in the prefrontal cortex after acute morphine and during morphine withdrawal. Psychopharmacology (Berl) 160:220-224.
17. Diana M, Pistis M, Muntoni A, Gessa G. 1995. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J Pharmacol Exp Ther 272:781-785.
18. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic DA concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
19. Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS. 1996. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of ΔFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8:365-381.
20. Downes GB, Gautam N. 1999. The G protein subunit gene families. Genomics 62:544-552.
21. Friedman E, Wang H-Y 1996. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 67:1145-1152.
22. Gardner EL. 2004. Brain-reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: A comprehensive textbook, 4th ed. Philadelphia: Lippincott Williams & Wilkins. p 48-97.
23. Grice DE, Reenilä I, Männistö PT, Brooks AI, Smith GG, Golden GT, Buxbaum JD, Berrettini WH. 2007. Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics 8:76. http://www.biomedcentral.com/ 1471-2164/8/76.
24. Hall FS, Li X-F, Goeb M, Roff S, Hoggatt H, Sora I, Uhl GR. 2003. Congenic C57BL/6 μ opiate receptor (MOR) knockout mice: Baseline and opiate effects. Genes Brain Behav 2:114-121.
25. Harlan RE, Garcia MM. 1998. Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 16:221-267.
26. A channel subtypes. Mol Neurobiol 18:35-86.
27. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ. 1994. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13:1235-1244.
28. Hudson CJ, Young LT, Li PP, Warsh JJ. 1993. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13:278-293.
29. Hwang J-I, Choi S, Fraser IDC, Chang MS, Simon MI. 2005. Silencing the expression of multiple Gβ-subunits eliminates signaling mediated by all four families of G proteins. Proc Natl Acad Sci USA 27:9493-9498.
30. Jacobs EH, Spijker S, Verhoog CW, Kamprath K, de Vries TJ, Smit AB, Schoffelmeer ANM. 2002. Active heroin administration induces specific genomic responses in the nucleus accumbens shell. FASEB J 16:1961-1963.
31. Johnston CA, Siderovski DP. 2007. Receptor-mediated activation of heterotrimeric G proteins: Current structural insights. Mol Pharmacol 72:219-230.
32. Kaewsuk S, Hutamekalin P, Ketterman AJ, Khotchabhakdi N, Govitrapong P, Casalotti SO. 2001. Morphine induces short-lived changes in G-protein gene expression in rat prefrontal cortex. Eur J Pharmacol 411:11-16.
33. Kalivas PW, Stewart J. 1991. DA transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223-244.
34. Kim DS, Lim HK, Jang S, Oh S. 2003. Changes of the level of G protein α-subunit mRNA by tolerance to and withdrawal from butorphanol. Neurochem Res 28:1771-1778.
35. Kim Y, Oh S. 2002. Changes of the levels of G protein α-subunit mRNA by tolerance to and withdrawal from pentobarbital in rats. Neurochem Res 27:527-533.
36. Kitanaka J, Kitanaka N, Takemura M, Wang X-B, Hembree CM, Goodman NL, Uhl GR. 2002. Isolation and sequencing of a putative promoter region of the murine G protein β1 subunit (GNB1) gene. DNA Seq 13:39-45.
37. Kitanaka J, Kitanaka N, Takemura M. 2003. Chronic methamphetamine administration reduces histamine-stimulated phosphoinositide hydrolysis in mouse frontal cortex. Biochem Biophys Res Commun 300:932-937.
38. Kitanaka J, Kitanaka N, Takemura M. 2008. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: A review. Neurochem Res 33:204-219.
39. Kitanaka N, Kitanaka J, Walther D, Wang X-B, Uhl GR. 2003. Comparative inter-strain sequence analysis of the putative regulatory region of murine psychostimulant-regulated gene GNB1 (G protein β1 subunit gene). DNA Seq 14:257-263.
40. Kitanaka N, Sora I, Kinsey S, Zeng Z, Uhl GR. 1998. No heroin or morphine 6β-glucuronide analgesia in μ-receptor knockout mice. Eur J Pharmacol 355:R1-R3.
41. + channels. Nature Neurosci 2:1091-1097.
42. Koob GF, Bloom FE. 1988. Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
43. 2-like receptors in vivo. Neuropharmacology 51:597-605.
44. Lee HJ, Cha JH, Ham BJ, Han CS, Kim YK, Lee SH, Ryu SH, Kang RH, Choi MJ, Lee MS. 2004. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorder. Pharmacogenomics J 4:29-33.
45. Leshner AI, Koob GF. 1999. Drugs of abuse and the brain. Proc Assoc Am Physicians 111:99-108.
46. 2 receptor agonist DOI. Eur J Pharmacol 221:121-127.
47. Lewohl JM, Wilson WR, Mayfield RD, Brozowski SJ, Morrisett RA, Harris RA. 1999. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci 2:1084-1090.
48. Mansour A, Lewis ME, Khachaturian H, Akil H, Watson SJ. 1986. Pharmacological and anatomical evidence of selective μ, δ and κ opioid receptor binding in rat brain. Brain Res 399:69-79.
49. McClung CA, Nestler EJ, Zachariou V. 2005. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. J Neurosci 25:6005-6015.
50. Neer EJ. 1995. Heterotrimeric G proteins: Organizers of transmembrane signals. Cell 80:249-257.
51. Nestler EJ. 1993. Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 7:23-39.
52. Nestler EJ, Erdos JJ, Terwilliger R, Duman RS, Tallman JF. 1989. Regulation of G proteins by chronic morphine in the rat locus coeruleus. Brain Res 476:230-239.
53. Nestler EJ, Berhow MT, Brodkin ES. 1996. Molecular mechanisms of drug addiction: Adaptations in signal transduction pathways. Mol Psychiatry 1:190-199.
54. Noble F, Cox BM. 1996. Differential desensitization of μ- and δ-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 117:161-169.
55. Olmstead MCBurns LH. 2005. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl) 181:576-581.
56. Olson VG, Zabetian CP, Bolanos CA, Edwards S, Barrot M, Eisch AJ, Hughes T, Self DW, Neve RL, Nestler EJ. 2005. Regulation of drug reward by cAMP response element-binding protein: Evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci 25:5553-5562.
57. Parolaro D, Rubino T, Gori E, Massi P, Bendotti C, Patrini G, Marcozzi C, Parenti M. 1993. In situ hybridization reveals specific increases in Gαs and Gαo mRNA in discrete brain regions of morphine-tolerant rats. Eur J Pharmacol 244:211-222.
58. Patel MB, Patel CN, Rajashekara V, Yoburn BC. 2002. Opioid agonists differentially regulate μ-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62:1464-1470.
59. Perrine SA, Schroeder JA, Unterwald EM. 2005. Behavioral sensitization to binge-pattern cocaine administration is not associated with changes in protein levels of four major G-proteins. Mol Brain Res 133:224-232.
60. Przewlocki R. 2004. Opioid abuse and brain gene expression. Eur J Pharmacol 500:331-349.
61. Reuveny E, Slesinger PA, Inglese J, Morales JM, Iniguez-Lluhi JA, Lefkowitz RJ, Bourne HR, Jan YN, Jan LY. 1994. Activation of the cloned muscarinic potassium channel by G protein beta gamma subunits. Nature 370:143-146.
62. Riegel AC, Zapata A, Shippenberg TS, French editors. 2007. The abused inhalant toluene increases DA release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology 32:1558-1569.
63. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198.
64. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro D. 1994. Effect of chronic exposure to naltrexone and opioid selective agonists on G protein mRNA levels in the rat nervous system. Mol Brain Res 23:333-337.
65. Rubino T, Parenti M, Patrini G, Massi P, Parolaro D. 1995. Morphine withdrawal syndrome and G protein expression: A study of the time course in the rat central nervous system. Eur J Neurosci 7:2334-2340.
66. Saito M, Smiley J, Toth R, Vadasz C. 2002. Microarray analysis of gene expression in rat hippocampus after chronic ethanol treatment. Neurochem Res 27:1221-1229.
67. A receptor complex. Prog Drug Res 34:261-286.
68. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 32:639-677.
69. Self DW, Nestler EJ. 1995. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463-495.
70. Selley DE, Nestler EJ, Breivogel CS, Childers SR. 1997. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment. Brain Res 746:10-18.
71. Shaw-Lutchman TZ, Barret M, Wallace T, Gilden L, Zachariou V, Impey S, Duman RS, Storm D, Nestler EJ. 2002. Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J Neurosci 22:3663-3672.
72. Sim-Selley LJ, Selly DE, Vogt LJ, Childers SR, Martin TJ. 2000. Chronic heroin self-administration desensitizes μ opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 20:4555-4562.
73. Sim-Selley LJ, Scoggins KL, Cassidy MP, Smith LA, Dewey WL, Smith FL, Selley DE. 2007. Region-dependent attenuation of μ opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance. Br J Pharmacol 151:1324-1333.
74. Simon MI, Strathmann MP, Gautam N. 1991. Diversity of G proteins in signal transduction. Science 252:802-808.
75. Sora I, Elmer G, Funada M, Pieper J, Li X-F, Hall FS, Uhl GR. 2001. μ Opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo μ receptor reverse. Neuropsychopharmacology 25:41-54.
76. Spiga S, Puddu MC, Pisano M, Diana M. 2005. Morphine withdrawal-induced morphological changes in the nucleus accumbens. Eur J Neurosci 22:2332-2340.
77. Stafford K, Gomes AB, Shen J, Yoburn BC. 2001. μ-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav 69:233-237.
78. Steketee JD. 2003. Neurotransmitter systems of the medial prefrontal cortex: Potential role in sensitization to psychostimulants. Brain Res Rev 41:203-228.
79. Sulzer D, Sonders MS, Poulsen NW, Galli A. 2005. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75:406-433.
80. A receptors are target for alcohol. Nat Neurosci 5:721-722.
81. Tao P-L, Law P-Y, Loh HH. 1987. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharmacol Exp Ther 240:809-816.
82. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ. 1991. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548:100-110.
83. Tian M, Broxmeyer HE, Fan Y, Lai Z, Zhang S, Aronica S, Cooper S, Bigsby RM, Steinmetz R, Engle SJ, Mestek A, Pollock JD, Lehman MN, Jansen HT, Ying M, Stambrook PJ, Tischfield JA, Yu L. 1997. Altered hematopoiesis, behavior, and sexual function in μ opioid receptor-deficient mice. J Exp Med 185:1517-1522.
84. Wang H-Y, Friedman E, Olmstead MC, Burns LH. 2005. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gβγ signaling. Neuroscience 135:247-261.
85. 1: A psychostimulant-regulated gene essential for establishing cocaine sensitization. J Neurosci 17:5993-6000.
86. Wise RA. 1987. The role of reward pathways in the development of drug dependence. Pharmacol Ther 35:227-263.
87. Wolf ME, Sun X, Mangiavacchi S, Chao SZ. 2004. Psychomotor stimulants and neuronal plasticity. Neuropharmacology 47:61-79.
88. Yao L, McFarland K, Fan P, Jiang Z, Inoue Y, Diamond I. 2005. Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc Natl Acad Sci USA 102:8746-8751.